With IT and pharma still continuing to see interest, the next series too looks promising for them, says Yogesh Radke, head of quantitative research at Edelweiss Securities.
first published: Mar 26, 2015 10:45 am
A collection of the most-viewed Moneycontrol videos.

New Year Party Or Year-End Blues? Bulls In Focus| Top Stock Bets & 2026 Outlook| Opening Bell Live

Nifty Trades in a Narrow 100-Point Range on 2025’s Final F&O Expiry | Closing Bell Live

Small-Caps & Risk: What Investors Often Miss

Nifty’s Best Case Target & Top Stock Bets For 2026| IPO Wave Set To Get Bigger| Opening Bell Live
You are already a Moneycontrol Pro user.

